- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Cancer Epidemiology
Volume 2012 (2012), Article ID 294730, 11 pages
Patterns of Cancer Genetic Testing: A Randomized Survey of Oregon Clinicians
1Oregon Genetics Program, Public Health Division, Oregon Health Authority, Portland, OR 97232, USA
2Oregon Center for Children and Youth with Special Health Needs, Child Development and Rehabilitation Center, Oregon Health & Science University, Portland, OR 97239, USA
3Survey Research Lab, Office of Research and Sponsored Projects, Portland State University, Portland, OR 97201, USA
4Center for Public Health Practice, Public Health Division, Oregon Health Authority, Portland, OR 97232, USA
Received 16 March 2012; Revised 11 June 2012; Accepted 12 June 2012
Academic Editor: Suzanne C. O'Neill
Copyright © 2012 Summer L. Cox et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- “American Cancer SocietyCancer Facts and Figures,” 2010, http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf.
- NCI National Cancer Institute, “Genetics of Breast and Ovarian Cancer—PDQ Summary,” 2012, http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/healthprofessional/.
- National Cancer Institute (NCI), “BRCA1 and BRCA2: Cancer Risk and Genetic Testing,” 2009, http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA.
- S. Chen and G. Parmigiani, “Meta-analysis of BRCA1 and BRCA2 penetrance,” Journal of Clinical Oncology, vol. 25, no. 11, pp. 1329–1333, 2007.
- National Cancer Institute (NCI), “Genetics of Colorectal Cancer—PDQ Summary,” 2012, http://www.cancer.gov/cancertopics/pdq/genetics/colorectal/healthprofessional.
- W. S. B. Kohlmann, S. B. Gruber, and L. Syndrome, “GeneReviews at GeneTests: Medical Genetics Information Resource,” 2004, http://www.ncbi.nlm.nih.gov/books/NBK1211/.
- National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology—Colorectal Cancer Screening, 2010.
- National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology—Genetic/Familial High-Risk Assessment: Breast and Ovarian, 2010.
- Intergenetics Incorporated, What is OncoVue, 2012, http://www.intergenetics.com/cms/technologyandproducts/whatisoncovue.
- Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, “Recommendations from the EGAPP working group: can UCT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?” Genetics in Medicine, vol. 11, no. 1, pp. 15–20, 2009.
- Evaluation of Genomic Applications in Practice and Prevention (EGAPP), “Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives,” Genetics in Medicine, vol. 11, no. 1, pp. 35–41, 2009.
- Evaluation of Genomic Applications in Practice and Prevention (EGAPP), “Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?” Genetics in Medicine, vol. 11, no. 1, pp. 66–73, 2009.
- M. Tzvetkov and N. von Ahsen, “Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era,” Pathology, vol. 44, no. 2, pp. 166–180, 2012.
- U.S. Preventive Services Task Force (USPSTF), “The Guide to Clinical Preventive Services. 2010-2011,” 2010.
- R. G. Watson and H. L. McLeod, “Pharmacogenomic contribution to drug response,” Cancer Journal, vol. 17, no. 2, pp. 80–88, 2011.
- D. B. White, V. L. Bonham, J. Jenkins, N. Stevens, and C. M. McBride, “Too many referrals of low-risk women for BRCA1/2 genetic services by family physicians,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 11, pp. 2980–2986, 2008.
- M. J. H. Baars, L. Henneman, and L. P. Ten Kate, “Deficiency of knowledge of genetics and genetic tests among general practitioners, gynecologists, and pediatricians: a global problem,” Genetics in Medicine, vol. 7, no. 9, pp. 605–610, 2005.
- N. Drury, J. Bethea, P. Guilbert, and N. Qureshi, “Genetics support to primary care practitioners—a demonstration project,” Journal of Genetic Counseling, vol. 16, no. 5, pp. 583–591, 2007.
- B. S. Flynn, M. E. Wood, T. Ashikaga, A. Stockdale, G. S. Dana, and S. Naud, “Primary care physicians' use of family history for cancer risk assessment,” BMC Family Practice, vol. 11, article 45, 2010.
- J. H. Medalie, S. J. Zyzanski, M. A. Goodwin, and K. C. Stange, “Two physician styles of focusing on the family: their relation to patient outcomes and process of care,” Journal of Family Practice, vol. 49, no. 3, pp. 209–215, 2000.
- P. W. Rose, E. Watson, P. Yudkin et al., “Referral of patients with a family history of breast/ovarian cancer—GPs' knowledge and expectations,” Family Practice, vol. 18, no. 5, pp. 487–490, 2001.
- R. D. Sifri, R. Wender, and N. Paynter, “Cancer risk assessment from family history: gaps in primary care practice,” The Journal of Family Practice, vol. 51, no. 10, p. 856, 2002.
- S. Suther and P. Goodson, “Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature,” Genetics in Medicine, vol. 5, no. 2, pp. 70–76, 2003.
- National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology—Colon Cancer, 2010.
- StataCorp, Stata statistical software for professionals, Version 19.0, College Station, Tex, USA, 2012.
- M. F. Myers, M. H. Chang, C. Jorgensen et al., “Genetic testing for susceptibility to breast and ovarian cancer: evaluating the impact of a direct-to-consumer marketing campaign on physicians' knowledge and practices,” Genetics in Medicine, vol. 8, no. 6, pp. 361–370, 2006.
- Centers for Disease Control and Prevention (CDC) and P.H.G., “Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing—Atlanta, Denver, Raleigh-Durham, and Seattle, 2003,” Morbidity and Mortality Weekly Report, pp. 603–606, 2004.
- National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology—Breast Cancer, 2010.
- D. Fumagalli, C. Desmedt, M. Ignatiadis, et al., “Gene profiling assay and application: the predictive role in primary therapy,” Journal of the National Cancer Institute Monographs, no. 43, pp. 124–127, 2011.
- L. J. van't Veer, H. Dai, M. J. Van de Vijver et al., “Gene expression profiling predicts clinical outcome of breast cancer,” Nature, vol. 415, no. 6871, pp. 530–536, 2002.
- L. Acheson, “Fostering applications of genetics in primary care: what will it take?” Genetics in Medicine, vol. 5, no. 2, pp. 63–65, 2003.
- S. B. Haga, M. M. Carrig, J. M. O'Daniel et al., “Genomic risk profiling: attitudes and use in personal and clinical care of primary care physicians who offer risk profiling,” Journal of General Internal Medicine, vol. 26, no. 8), pp. 834–840, 2011.
- S. E. Straus, J. Tetroe, and I. Graham, “Defining knowledge translation,” Canadian Medical Association Journal, vol. 181, no. 3-4, pp. 165–168, 2009.
- K. L. Brierley, D. Campfield, W. Ducaine et al., “Errors in delivery of cancer genetics services: implications for practice,” Connecticut Medicine, vol. 74, no. 7, pp. 413–423, 2010.
- K. F. Trivers, L. M. Baldwin, J. W. Miller et al., “Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a Vignette-Based Study,” Cancer, vol. 117, no. 23, pp. 5334–5343, 2011.
- T. Doksum, B. A. Bernhardt, and N. A. Holtzman, “Does knowledge about the genetics of breast cancer differ between nongeneticist physicians who do or do not discuss or order BRCA testing?” Genetics in Medicine, vol. 5, no. 2, pp. 99–105, 2003.
- A. N. Freedman, L. Wideroff, L. Olson et al., “US physicians' attitudes toward genetic testing for cancer susceptibility,” American Journal of Medical Genetics, vol. 120, no. 1, pp. 63–71, 2003.
- L. Wideroff, S. T. Vadaparampil, M. H. Greene, S. Taplin, L. Olson, and A. N. Freedman, “Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians,” Journal of Medical Genetics, vol. 42, no. 10, pp. 749–755, 2005.